Financial Snapshot

Revenue
$30.28M
TTM
Gross Margin
70.02%
TTM
Net Earnings
-$80.12M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
807.97%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$30.71M
Q3 2024
Cash
Q3 2024
P/E
-2.161
Nov 29, 2024 EST
Free Cash Flow
-$52.85M
TTM

Revenues

Revenues

Revenue YoY Change

No data

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $13.59M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $13.59M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue $3.811M
Gross Profit $9.782M
Gross Profit Margin 71.96%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Selling, General & Admin $53.37M $20.62M $9.784M $11.78M $8.270M $13.72M $9.110M $6.050M $2.580M
YoY Change 158.77% 110.79% -16.94% 42.44% -39.72% 50.6% 50.58% 134.5%
% of Gross Profit 545.58%
Research & Development $11.81M $15.53M $16.04M $18.15M $24.63M $15.95M $14.33M $11.86M $8.270M
YoY Change -23.97% -3.15% -11.63% -26.32% 54.45% 11.28% 20.88% 43.36%
% of Gross Profit 120.72%
Depreciation & Amortization $24.00K $37.00K $34.00K $34.00K $37.00K $38.00K $17.00K $5.000K $0.00
YoY Change -35.14% 8.82% 0.0% -8.11% -2.63% 123.53% 240.0%
% of Gross Profit 0.25%
Operating Expenses $65.18M $36.16M $25.82M $29.93M $24.63M $29.67M $23.44M $17.91M $10.84M
YoY Change 80.26% 40.02% -13.73% 21.52% -16.97% 26.59% 30.85% 65.22%
Operating Profit -$55.40M -$36.16M -$25.82M -$29.93M -$32.91M -$29.67M -$23.44M -$17.91M
YoY Change 53.21% 40.02% -13.73% -9.03% 10.91% 26.59% 30.85%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Interest Expense $8.123M $3.302M $2.575M $2.587M $1.767M $1.432M -$460.0K -$6.510M $0.00
YoY Change 146.0% 28.23% -0.46% 46.41% 23.39% -411.3% -92.93%
% of Operating Profit
Other Income/Expense, Net $3.605M $1.418M $315.0K -$4.000K $20.00K -$56.00K $75.00K $38.00K $330.0K
YoY Change 154.23% 350.16% -7975.0% -120.0% -135.71% -174.67% 97.37% -88.48%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Pretax Income -$54.81M -$36.84M -$28.03M -$32.21M -$33.00M -$29.44M -$23.82M -$24.38M -$10.52M
YoY Change 48.79% 31.4% -12.96% -2.39% 12.09% 23.59% -2.3% 131.75%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$54.81M -$36.84M -$28.03M -$32.21M -$33.00M -$29.44M -$23.82M -$24.38M -$10.52M
YoY Change 48.79% 31.4% -12.96% -2.39% 12.07% 23.62% -2.3% 131.72%
Net Earnings / Revenue -403.22%
Basic Earnings Per Share -$1.42 -$1.30 -$1.02
Diluted Earnings Per Share -$1.42 -$1.30 -$1.141M -$1.311M -$1.774M -$1.586M -$1.285M -$1.384M -$597.4K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

No data

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Cash & Short-Term Investments $76.01M $118.2M $75.28M $105.1M $72.60M $89.50M $118.3M $39.30M $1.600M
YoY Change -35.68% 57.0% -28.37% 44.77% -18.88% -24.34% 201.02% 2356.25%
Cash & Equivalents $46.81M $71.06M $74.27M $71.80M $72.60M $89.50M $118.3M $39.30M $1.600M
Short-Term Investments $29.20M $47.13M $1.010M $33.30M
Other Short-Term Assets $3.596M $3.892M $2.997M $2.700M $2.700M $2.000M $900.0K $100.0K $100.0K
YoY Change -7.61% 29.86% 11.0% 0.0% 35.0% 122.22% 800.0% 0.0%
Inventory $8.840M $1.230M
Prepaid Expenses
Receivables $4.489M
Other Receivables $0.00
Total Short-Term Assets $92.94M $123.3M $78.28M $107.8M $75.60M $91.90M $119.9M $39.70M $1.800M
YoY Change -24.63% 57.53% -27.39% 42.59% -17.74% -23.35% 202.02% 2105.56%
Property, Plant & Equipment $1.459M $620.0K $479.0K $900.0K $1.300M $1.700M $2.000M $0.00 $0.00
YoY Change 135.32% 29.44% -46.78% -30.77% -23.53% -15.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $82.00K $267.0K $283.0K $300.0K $300.0K $200.0K $200.0K $0.00 $0.00
YoY Change -69.29% -5.65% -5.67% 0.0% 50.0% 0.0%
Total Long-Term Assets $1.541M $887.0K $762.0K $1.200M $1.700M $1.900M $2.100M $100.0K $0.00
YoY Change 73.73% 16.4% -36.5% -29.41% -10.53% -9.52% 2000.0%
Total Assets $94.48M $124.2M $79.04M $109.0M $77.30M $93.80M $122.0M $39.80M $1.800M
YoY Change
Accounts Payable $4.001M $1.518M $544.0K $1.700M $1.100M $600.0K $1.600M $1.500M $700.0K
YoY Change 163.57% 179.04% -68.0% 54.55% 83.33% -62.5% 6.67% 114.29%
Accrued Expenses $9.077M $5.807M $4.466M $5.200M $4.000M $3.100M $3.100M $2.200M $1.300M
YoY Change 56.31% 30.03% -14.12% 30.0% 29.03% 0.0% 40.91% 69.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $9.805M $2.400M $0.00 $2.800M $300.0K
YoY Change -100.0% 308.54% -100.0% 833.33%
Total Short-Term Liabilities $13.13M $7.416M $14.85M $9.300M $5.200M $6.700M $5.200M $3.700M $2.000M
YoY Change 77.1% -50.05% 59.63% 78.85% -22.39% 28.85% 40.54% 85.0%
Long-Term Debt $38.81M $36.79M $7.354M $16.90M $18.90M $6.800M $9.100M $0.00 $0.00
YoY Change 5.48% 400.33% -56.49% -10.58% 177.94% -25.27%
Other Long-Term Liabilities $5.316M $7.552M $367.0K $700.0K $1.800M $1.500M $1.700M $0.00 $0.00
YoY Change -29.61% 1957.77% -47.57% -61.11% 20.0% -11.76%
Total Long-Term Liabilities $44.13M $44.35M $7.721M $17.60M $20.70M $8.300M $10.80M $0.00 $0.00
YoY Change -0.49% 474.36% -56.13% -14.98% 149.4% -23.15%
Total Liabilities $57.26M $51.76M $22.57M $26.90M $25.90M $15.00M $16.10M $3.700M $2.000M
YoY Change 10.62% 129.37% -16.11% 3.86% 72.67% -6.83% 335.14% 85.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Basic Shares Outstanding 38.51M 28.36M 27.35M
Diluted Shares Outstanding 38.51M 28.36M 27.35M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $173.14 Million

About scPharmaceuticals Inc.

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 135 full-time employees. The company went IPO on 2017-11-17. The firm is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The firm develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

Industry: Pharmaceutical Preparations Peers: Lyra Therapeutics, Inc. Citius Pharmaceuticals, Inc. DURECT CORP Ikena Oncology, Inc. JOHNSON & JOHNSON MARIMED INC. Paratek Pharmaceuticals, Inc. ProPhase Labs, Inc.